We serve Chemical Name:4H-pyrrolo[2,3-d][1,3]oxazole-5-carboxylic acid CAS:1041421-52-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![4H-pyrrolo[2,3-d][1,3]oxazole-5-carboxylic acid](https://a.dearchem.com/CAS2/1041421-52-6.png)
Chemical Name:4H-pyrrolo[2,3-d][1,3]oxazole-5-carboxylic acid
CAS.NO:1041421-52-6
Synonyms:4H-1-Oxa-3,4-diaza-pentalene-5-carboxylic acid
Molecular Formula:C6H4N2O3
Molecular Weight:152.10800
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:79.12000
Exact Mass:152.02200
LogP:0.85410
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4H-1-Oxa-3,4-diaza-pentalene-5-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4H-1-Oxa-3,4-diaza-pentalene-5-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4H-1-Oxa-3,4-diaza-pentalene-5-carboxylic acid Use and application,4H-1-Oxa-3,4-diaza-pentalene-5-carboxylic acid technical grade,usp/ep/jp grade.
Related News: The FDA has already clashed with COVID vaccine heavyweights Pfizer and BioNTech over the immediate need for boosters for the broader population. While the drugmakers argue a third shot would offer the highest level of protection, both the CDC and FDA immediately came out against that assertion. 1H-Pyrrole, 3,4-bis(3-chloro-2-methylphenyl)-2,5-dimethyl- manufacturers The outlay will be used to grow Takeda’s portfolio of treatments and boost capacity to manufacture additional products for the rare disease community, Stephen Hatke, Takeda’s Thousand Oaks site head, said in a YouTube video about the expansion. The company didn’t name the specific products it plans to make there. 5-Ethyl-2-methyl-piperidine-1-carbothioic acid S-p-tolyl ester suppliers The Institute for Clinical and Economic Review (ICER) on Friday released its report examining the cost-effectiveness of Soliris, also known as eculizumab, as well as up-and-comer efgartigimod for patients with the myasthenia gravis. (Z)-2-(5-fluoro-3,3-dimethyl-3,4-dihydro-(2H)-isoquinolin-1-ylidene)-1-phenylethan-1-one vendor & factory.
